<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Inhibition of Aurora kinase B has been evaluated as a therapy to block <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> growth in <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo>, <z:mp ids='MP_0002027'>lung adenocarcinoma</z:mp>, and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> models </plain></SENT>
<SENT sid="1" pm="."><plain>Aurora kinase inhibitors are in early clinical trials for the treatment of <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesized that Aurora B inhibition would reduce malignant <z:hpo ids='HP_0009733'>glioma</z:hpo> cell viability and result in impaired <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in vivo </plain></SENT>
<SENT sid="3" pm="."><plain>Aurora B expression is greater in cultured malignant <z:hpo ids='HP_0009733'>glioma</z:hpo> U251 cells compared to proliferating <z:mpath ids='MPATH_458'>normal</z:mpath> human astrocytes, and expression is maintained in U251 flank xenografts </plain></SENT>
<SENT sid="4" pm="."><plain>Aurora B inhibition with AZD1152-HQPA blocked cell division in four different p53-mutant <z:hpo ids='HP_0009733'>glioma</z:hpo> cell lines (U251, T98G, U373, and U118) </plain></SENT>
<SENT sid="5" pm="."><plain>AZD1152-HQPA also inhibited Aurora C activation loop threonine autophosphorylation at the effective antiproliferative concentrations in vitro </plain></SENT>
<SENT sid="6" pm="."><plain>Reduction in cell viability of U251 (p53(R273H)) cells was secondary to cytokinesis blockade and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induction following endoreplication </plain></SENT>
<SENT sid="7" pm="."><plain>AZD1152-HQPA inhibited the growth of U251 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> xenografts and resulted in an increase in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> both in vitro and in vivo </plain></SENT>
<SENT sid="8" pm="."><plain>Subcutaneous administration of AZD1152-HQPA (25 mg/kg/day Ã— 4 days; 2 cycles spaced 7 days apart) resulted in a prolongation in median survival after intracranial inoculation of U251 cells in mice (P = 0.025) </plain></SENT>
<SENT sid="9" pm="."><plain>This is the first demonstration that an Aurora kinase inhibitor can inhibit malignant <z:hpo ids='HP_0009733'>glioma</z:hpo> growth in vivo at drug doses that are clinically relevant </plain></SENT>
</text></document>